Immunic (IMUX) FY 2025 Conference February 12, 2025 01:20 PM ET Company Participants Jason Tardio - President & COODaniel Vitt - CEO & Director Conference Call Participants Andreas Argyrides - Managing Director & Senior Analyst - Biotechnology Andreas Argyrides Good. Great. Good afternoon, everyone, and welcome to Oppenheimer's thirty fifth Annual Healthcare Life Science Conference. My name is Andreas Zargaridis. I'm one of the senior biotech analysts at Oppenheimer. And today, I have the pleasure to be joi ...

Core Insights - Immunic, Inc. is actively participating in several investor and scientific conferences throughout February 2025, showcasing its commitment to engaging with stakeholders and presenting its clinical developments [1][2][4] Conference Participation - February 10-11: Immunic's CEO, Daniel Vitt, will engage in one-on-one meetings at the BIO CEO & Investor Conference in New York [2] - February 11-12: Dr. Vitt will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, with a webcast available on Immunic's website [2] - February 19-22: Immunic's team will attend the 19th Congress of ECCO in Berlin, presenting two abstracts on IMU-856, an orally available small molecule modulator targeting Sirtuin 6 [2][4] - February 25-27: Dr. Hella Kohlhof will present on vidofludimus calcium (IMU-838) at the 7th Neuroimmunology Drug Development Summit in Boston [2][4] - February 27 - March 1: Immunic will participate in the ACTRIMS Forum 2025 in West Palm Beach, Florida, with two abstracts accepted for poster presentations [2][3] Product Development - Immunic's lead asset, vidofludimus calcium (IMU-838), is in phase 3 and phase 2 clinical trials for relapsing and progressive multiple sclerosis, showing therapeutic activity in previous trials [4] - IMU-856 is designed to restore intestinal barrier function and is preparing for a phase 2 clinical trial, targeting gastrointestinal diseases [4] - IMU-381 is in preclinical testing, aimed at addressing gastrointestinal disease needs [4] Presentation Details - At the ECCO Congress, two presentations will focus on IMU-856: one on its effects from a Phase 1 clinical study and another on its preclinical characterization [2] - The presentation on vidofludimus calcium will highlight its dual role in neuroprotection and relapse prevention in multiple sclerosis [2]

Core Insights - Immunic Inc is advancing its novel therapy vidofludimus calcium, with significant milestones achieved in 2024, including a positive interim analysis of the ENSURE trials for relapsing multiple sclerosis and anticipation of results from the CALLIPER progressive MS study in April 2025 [1][5][7] Company Overview - Immunic is focused on a differentiated pipeline, strong leadership, and patient-centric priorities, with vidofludimus calcium having the potential to transform the multiple sclerosis treatment landscape [4] - The company has also been working on its second clinical program, IMU-856, targeting Sirtuin 6 for gastrointestinal conditions [2][4] Recent Developments - In 2024, Immunic achieved a positive interim analysis in its Phase 3 ENSURE program for relapsing forms of multiple sclerosis, with the independent data monitoring committee recommending the continuation of trials [5][6] - The company has expanded its scientific and medical presence through publications and presentations, enhancing visibility in the multiple sclerosis space [6] Financial Position - Immunic secured a three-tranche private placement totaling $240 million, which strengthens its financial base for ongoing and future projects [6] Future Outlook - 2025 is expected to be pivotal for Immunic, with the CALLIPER study's top-line results anticipated in April, focusing on vidofludimus calcium in progressive multiple sclerosis [7] - The company will continue advancing the ENSURE 1 and ENSURE 2 Phase 3 trials for relapsing multiple sclerosis, with enrollment progressing well [7] Product Differentiation - Vidofludimus calcium features a dual mechanism that addresses both neuroinflammation and neurodegeneration, making it suitable for both relapsing and progressive MS [8] - It is a selective DHODH inhibitor with proven anti-inflammatory effects and neuroprotective properties, showing strong results in interim analyses, including reductions in neural filament light levels, a biomarker for neurodegeneration [9] - Unlike other oral therapies, vidofludimus calcium has no black box warnings, indicating a favorable safety profile, and could potentially be the first oral therapy approved for both relapsing and progressive MS [9]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 – – Strengthened Management Team and Board of Directors with Key Hires – – Announced a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 202 ...

 NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 5, 2024, at 11:30 am ET, during the Piper Sandler 36th Annual Healthcare Conference, taking place December 3-5, 2024, in New York.Dr. Vitt, Glenn Whaley ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

– Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients –NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), has been publi ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...